(Total Views: 444)
Posted On: 09/23/2024 2:17:18 PM
Post# of 154757
Quote:
Apparently Medicenna is trying to do just that with MDNA11, an IL-2 Superkine that has enhanced binding to IL-2Rbeta and no IL-2Ralpha binding.
A step in the right direction. Now add multiple drugs that address other tumor protectant factors, one that addresses metastatic tumor cell movement, one that addresses angiogenesis and one that addresses the other immune dysregulation/inflammation that drives it all.
(10)
(0)
